Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

348257

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Antimicrobials: Drug Resistance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his Department has to make additional funding available to tackle drug-resistant infections over the next five years.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	1028
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>The health and care system across the United Kingdom is taking action against the growing threat of infections that are resistant to the antimicrobial drugs used to treat them.</p><p> </p><p> </p><p> </p><p>In December 2014, we published the UK Five Year AMR Strategy detailed implementation plan. The plan set out those activities that needed to be undertaken to deliver the strategy in each of seven key areas for action. Activity in the plan is led by the Department of Health, Public Health England, Department for Environment, Food and Rural Affairs and NHS England and is incorporated within existing business plans for those organisations.</p><p> </p><p> </p><p> </p><p>The Government has no current plans to make additional funding available to tackle drug-resistant infections. Any proposals for funding would be subject to the outcome of the Spending Review later this year.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/06/2015 10:54:59 answering member 3918 label Biography information for Jane Ellison
tabling member	308 label Biography information for Mr Jim Cunningham

348258

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Infectious Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the number of drug-resistant infections (a) in the West Midlands and (b) nationally in the next five years.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	1029
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Public Health England (PHE) has published no estimates for the number of drug-resistant infections in the West Midlands or nationally over the next five years. The science of drug resistant infections is incompletely understood and is rapidly changing and evolving. Multi-drug resistant infections are unpredictable in their occurrence and can rapidly change. For these reasons producing estimates of the likely burden in future years is unlikely to be meaningful or robust.</p><p> </p><p> </p><p> </p><p>Antimicrobial resistance is a priority for PHE who are working to improve surveillance and knowledge in this area. Specific antimicrobial resistant infections have been measured by PHE and openly published in weekly Health Protection Reports.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/06/2015 10:58:32 answering member 3918 label Biography information for Jane Ellison
tabling member	308 label Biography information for Mr Jim Cunningham

348273

registered interest
date	03/06/2015
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Crime: Victims
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Justice, when he plans to publish legislative proposals to increase the rights of victims of crime.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	1067
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>We will publish draft clauses in due course.</p> answering member constituency Hemel Hempstead answering member printed Mike Penning question first answered 08/06/2015 11:36:40 answering member 1528 label Biography information for Sir Mike Penning
tabling member	4243 label Biography information for Dan Jarvis

348276

registered interest
date	03/06/2015
answering body	Department for Energy and Climate Change
answering dept id	63
answering dept short name	Energy and Climate Change
answering dept sort name	Energy and Climate Change
hansard heading	Wind Power
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Energy and Climate Change, if she will take steps to reduce the subsidies available to the promotion and construction of on-shore wind farms; and if she will bring forward proposals to ensure that local planning controls over such projects involve adequate consultation with local residents before consent is granted.
tabling member constituency	North Thanet
tabling member printed	Sir Roger Gale
uin	954
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>We are driving forward plans to deliver our manifesto pledge to end new subsidies for onshore wind and to give local communities the final say on windfarm applications as soon as possible. We will publish our plans and timetable for these changes shortly.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 08/06/2015 09:58:46 answering member 4117 label Biography information for Andrea Leadsom
tabling member	87 label Biography information for Sir Roger Gale

348397

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa: Health Education
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to raise awareness of hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	962
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 963 964 965 question first answered 08/06/2015 10:53:58 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

348398

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate his Department has made of the number of people with hidradenitis suppurativa in the UK; how much his Department has spent on research into hidradenitis suppurativa in the last four years; and what guidance his Department gives on support to be given through the NHS for people with hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	963
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 962 964 965 question first answered 08/06/2015 10:54:00 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

348399

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the effectiveness of the care pathways for patients with hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	964
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 962 963 965 question first answered 08/06/2015 10:54:00 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper